| Characteristic | N (%) |
| Age |
|
| Median | 65 |
| Range | 41 - 86 |
| <75 | 60 (83.3) |
| Male | 47 (65.3) |
| Race |
|
| White | 37 (51.4) |
| Black | 30 (41.7) |
| Other | 3 (4.2) |
| ECOG PSa |
|
| 0 | 26 (36.1) |
| 1 | 36 (50) |
| 2 | 10 (13.9) |
| 3 | 0 (0) |
| Smoking historyb |
|
| Light/never | 18 (25) |
| Heavy | 51 (70.8) |
| Histology |
|
| Non-squamous | 57 (79.2) |
| Squamous | 15 (20.8) |
| Targetable driver mutationc |
|
| EGFR | 9 (12.5) |
| ALK | 0 |
| ROS-1 | 0 |
| Site of metastases at initiation of therapy |
|
| Bone | 20 (27.8) |
| Liver | 13 (18.1) |
| Brain | 11 (15.3) |
| Line of therapy |
|
| 2 | 36 (50) |
| 3 | 20 (27.8) |
| 4+ | 9 (12.5) |
| Therapy |
|
| Nivolumab | 54 (75) |
| Pembrolizumab | 18 (25) |
| dNLR |
|
| <3 | 55 (76.4) |
| ≥3 | 17 (23.6) |